For intravenous use only. Administer as a continuous infusion via an infusion pump. Dilute prior to administration. Do not mix with sodium bicarbonate or other alkaline solutions.

Dobutamine selectively stimulates beta-1 adrenergic receptors, primarily increasing myocardial contractility and stroke volume, leading to increased cardiac output. It has relatively mild chronotropic, alpha-adrenergic, and beta-2 adrenergic effects at therapeutic doses. It increases myocardial contractility without significantly increasing heart rate or systemic vascular resistance.

• •Idiopathic hypertrophic subaortic stenosis (IHSS).
• •Patients with known hypersensitivity to dobutamine or to any component of the formulation.

Store at controlled room temperature 20-25°C (68-77°F). Protect from light. Do not freeze. Diluted solutions are stable for 24-48 hours under refrigeration or at room temperature.

Symptoms include excessive beta-stimulation: hypertension, tachycardia, myocardial ischemia, ventricular fibrillation, and possibly vasodilation. Management involves reducing the rate of administration or discontinuing the infusion. Correct hypokalemia if present. Gastric lavage and activated charcoal are generally not indicated. In case of serious arrhythmias, a beta-adrenergic blocking agent may be considered.

Pregnancy Category B. Use only if clearly needed. It is not known whether dobutamine is excreted in human milk. Exercise caution when administering to a nursing woman.